These studies should precisely account for various confounding variables, including lipid fluctuations (59), different genetic variations (such as APOE, LDLR, CETP, etc.)(60, 61), guidelines for treatment of dyslipidemia, statin dosage (62, 63), and sex differences (64), to minimize bias and accurately quantify the specific cognitive benefits of statins for individuals with dyslipidemia. This evidence concerns the gene APOE and metabolic syndrome.